期刊文献+

64例狼疮性肾炎大剂量环磷酰胺冲击治疗的研究 被引量:4

Study on Bolus Cyclosphamide Treament for 64 Cases of Lupu s Nephritis
暂未订购
导出
摘要 目的 观察大剂量环磷酰胺冲击治疗狼疮性肾炎的疗效。方法 对 6 4例狼疮肾炎 ( L N ,其尿红细胞 >10个 /高倍视野 ,2 4小时尿蛋白 >1g,血肌酐 >133μmol/ L )进行大剂量环磷酰胺 ( CTX)冲击治疗 (每月 1次 ,共 6次 ,其后每 3月 1次 ,共 6次 )。结果  49例 L N患者达到肾脏损害缓解 ( 2 4小时尿蛋白 <1g;血肌酐 <133μmol/ L ;尿沉渣内红细胞 <10个 /高倍视野 ;尿管型消失 )。达到肾脏病变缓解所需冲击次数平均为 3.6次 ( 1~8次 )。每次用 CTX剂量均数 1.1g( 0 .6~ 1.6 g)。副作用有闭经 (发生率 33% ) ;带状疱疹 (发生率 13% ) ;出血性膀胱炎 1例。结论 此治疗方案治疗 L N有效 ,安全 。 Objective To report on the dosing, efficacy and s ide effects of bolus cyclosphamide treatment for lupus nephritis (LN). Methods 64 consecuti ve cases of LN with 10 or more erythrocytes per high power field, proteinuri a (>1g of protein per day ) and serum creatinine increased (>133μmol/L) were tre ated by bolus therapy with cyclophosphamide (CTX) given monthly for 6 months and then quarterly for 18 months. Results 49 patients had renal remission (defin ed as <10 erythrocytes per high power field, absence of cellular casts, excreti o n of <1g of protein per day and normal serum creatinine). The mean of doses was 1.1g for each time (0 6 1.6g ), the mean of times of bolus CTX needed was 3.6 (1 8 times). The adverse events were amenorrhea (in 41% female patients), herpes z oster (in 13% patients ) and hemorrhagic cystitis (in 1 patient). Conclu sion The results indicate that monthly bolus CTX therapy is effective and safe for patients with LN. Its adverse effect is relatively not a serious p roblem.
出处 《华西医科大学学报》 CAS CSCD 北大核心 2001年第1期129-130,139,共3页 Journal of West China University of Medical Sciences
关键词 狼疮性肾炎 环磷酰胺 冲击治疗 大剂量 Lupus nephritis Cyclophosphamide Bolus th erapy Renal lesion
  • 相关文献

参考文献7

  • 1[1]Donadio JV,Glassock RJ .Immunosuppressive drug therapy in lupus nephritis. Ameri J kidney disea,1993;21(3):239
  • 2[2]Bansal VK,Beto JA.Treatment of lupus nephritis:A meta-analysis o f clinical trials. Ameri J Kidney Disea,1997;29(2):193
  • 3[3]Faedda R,Palomba D,Satta A, et al .Immunosuppressive trea tme nt of the glomerulonephritis of systemic lupus .Cninical Nephrology,1995;44(6 ):367
  • 4[4]Balow JE, Boumpas DT,Fessler BJ, et al. Management of lupus nephritis. Kidney international,1996;49(Suppl53):S-88
  • 5[5]Out HJ, Groot PGD, Hasselaar P,et al. Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis,1989;48(12):1023
  • 6[6]Gourley MF, Austin Ⅲ HA, Scott D, et al. Methyl-predniso lone and Cyclophosphamide, Alone or in combination, in patients with lupus nep hrit is. Ann Intern Med,1996;125(7):549
  • 7[7]Conlon PJ, Fischer CA,Levesque MC,et al.Clinical,biochemi cal and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.Clinical Nephrology,1996;46(3) :170

同被引文献31

  • 1彭学标.雷公藤对系统性红斑狼疮外周血单一核细胞CD40配体mRNA表达的影响[J].中国麻风皮肤病杂志,2004,20(6):550-551. 被引量:7
  • 2李荣芬.狼疮性肾炎的诊治进展[J].河北医药,2006,28(1):61-62. 被引量:3
  • 3Houssiau FA,Vasconcelos C,D'Cruz D,et al.Immunosuppressive therapy in lupus nephritis.The Euro-Lupus Nephritis Trial,a randomized trial of low-dose versus high-dose intravenous cyclophosphamide[J].Arthritis Rheum,2002,46:2121-2131.
  • 4Ellen MG,Mary AD,Cynthia A,et al.Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis[J].N Engl J Med,2005,353:2219-2228.
  • 5Contreras G,Pardo V,Leclercq B,et al.Maintenance therapy for proliferative forms of lupus nephritis:a randomizedclinical trial comparing quarterly IV cyclophosphamide(IVCY)versus oral mycophenolate mofetil(MMF)orazathioprine(AZA)[J].J Am Soc Nephrol,2002,13:AFC069.
  • 6Petera P,Manger K,Rosenburg R,et al.A pilot study of leflunomide in systemic lupus erythematosus[J].Arthritis Rheum,2000,43:S241-248.
  • 7Remer C,Weisman M,Wallace D.Benefits of leflunomide in systemic lupus erythematosus:a pilot observational study[J].Lupus,2001,10:480-483.
  • 8Mok CC,Tong KH,To CH,et al.Tacrolimus for induction therapy of diffuse proliferative lupus nephritis:an open-labeled pilot study[J].Kidney Int,2005,68(2):813-7.
  • 9Looney RJ,Anolik JH,Campbell D,et al.B Cell Depletion as a Novel Treatment for Systemic Lupus Erythematosus:A Phase I/II Dose-Escalation Trial of Rituximab[J].Arthritis Rheum,2004,50(8):2580-2589.
  • 10Stummvoll GH,Aringer M,Smolen JS et al.IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria:a long term observational study[J].Annals of the Rheumatic Diseases,2005,64(7):1015-1021.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部